CNS Neurotransmitters
Receptor determines action of NT
(ie, NTs are excitatory or inhibitory, and communication is complex between neurons, but the receptor itself determines the action of NT)
What specific characteristics must a substance have to cross the blood-brain barrier (BBB)?
BBB formed by endothelial cells and astrocytes that limits movement of substances into CNS
In order to cross, substances must be lipophilic and able to diffuse easily
Basal nuclei (basal ganglia) function
Regulates starting and stopping of skeletal muscle movements
Assists with starting and stopping of some cognitive functions associated with memory, learning and planning
Extrapyramidal System
Modulates motor activities associated with alpha motor neurons including reflex arcs, postural control and complex movements like walking
Tracts move through brainstem into spinal cord
Signals carried along these tracts are influenced by activity of basal nuclei
The Three D’s
Delerium - Acute onset, can be treated
* Altered state of consciousness
* Assessed using the CAM (see Care Plans)
Patients disoriented and fluctuating levels of consciousness.
Depression - Gradual onset, can be treated
* Look for signs, such as low self-esteem.
* Can coexist with other medical diagnoses. Need lifestyle modifications or ECC for fever cases
Dementia - Gradual onset, might be treated
* Memory loss and decline in cognitive function.
* Progresses slowly over months or years. Certain types are not fully reversible, but some can be caught and treated early (like vitamin deficiencies)
Geriatric Pharmacokinetics
Absorption –> Distribution –> Metabolism –> Excretion
Absorption: not affected significantly, maybe minor changes, like decreased gastric acid production, reduced GI motility, and this can impact some drugs
Distribution:
↘️ total body water
↗️ body fat
↘️ serum albumin
* older adult have less water in body, so some drug concentrations can be higher, and needs to be adjusted.
* Also, body fat up means slower metab.
Serum albumin decreased
Metabolism:
↘️ hepatic blood flow and metabolizing enzymes
* slower metab. so slower drug clearance, –> drugs have longer durations of action
Excretion:
↘️ renal function
* Reduced GFR, kidney clears meds slower.
Medications to treat primary symptoms - Cholinesterase Inhibitors
Cholinesterase inhibitors = donepezil, rivastigmine, galantamine
These drugs stop the breakdown of acetylcholine, which is an important neurotransmitter in memory and cognition.
* SO, since breakdown is reduced, it increases how much is available in the synapse.
Show modest improvement in cognition, function, and behaviour.
Response: 1/3 improve, 1/3 stabilize, 1/3 have no response.
Does not prevent the progression of underlying disease
Medications to treat primary symptoms - Memantine
Glutamate is a transmitter in the brain that is affected by Alzheimer’s Disease.
Blocks the pathological effects of abnormal glutamate release.
Allows for better function of the impaired brain.
Indicated for moderate to severe Alzheimer’s.
Trials show slowing in cognitive and functional decline, as well as ↘️ in agitation.
Risks associated with acute care admissions for patients with dementia.
What are the potential consequences of “risky” acute care admissions for dementia patients?
(Related to previous “Risks” card)
How to work with pts with Dementia
Show them you care/validate:
* Be mindful of tone of voice, facial expressions, word choices, gestures.
* Be able to listen to criticism, complaints, and sadness without invalidating, retaliating, or withdrawing.
MIScommunication can occur when:
* Eyeglasses are not being worn or are dirty
* Hearing aids aren’t in, or batteries are dead
* Dentures are out, unable to access nutrition
The DOs:
* Respect and dignity
* Explain clearly, keep short.
* Maintain eye contact
* Look directly at person, get their attention
* Be realistic in expectations
* Paraphrase and use calm, reassuring tone
* Encourage talk about things they are familiar with
* Therapeutic touch
The DON’Ts:
* No baby talk
* No complicated words
* Don’t NOT explain things that you are about to do
* Don’t Talk over distracting environment
* Don’t Provoke
* Don’t disregard you own non-verbals
* Don’t shout/talk too fast
* Don’t touch without permission
Describe the specific neurotransmitter imbalance in the striatum during Parkinson’s Disease.
Also, what is the normal physiology?
Normal Physiology: The striatium receives excitatory input from the cortex
* Mediated by the excitatory neurotransmitter, glutamate
There is a loss of inhibitory dopamine input from the substantia nigra (the neurons die), which fails to balance the excitatory glutamate input from the cortex.
Pathophysiology of Parkinson’s Disease (PD)
Death of dopamine-producing neurons projecting from the substantia nigra to the striatum.
Define the four characteristic motor problems of PD.
Degenerative disease in which dopamine-producing neurons in the basal ganglia die
* Neurons projecting from substantia nigra to striatum are affected
* Reduction in DA in this pathway leads to characteristic motor problems
Treatment of PD
Since Dopamine neurons are deteriorating then replace dopamine to restore balance
* Increasing available dopamine
* Give dopamine agonists
Levodopa/carbidopa: A first line therapy (many Neurologist will delay until symptoms are bothersome)
* Levodopa is the amino acid precursor to dopamine
* Carbidopa inhibits peripheral decarboxylation of levodopa so that enough can cross the blood brain barrier
DA doesn’t cross BBB, but levodopa DOES cross the BBB.
Agonist will stimulate receptors for what’s remaining.
Levodopa/carbidopa
First-line treatment for PD
Pharmacokinetics:
* When given as immediate release product
* Half 1-1.5 hours
* Slow-release product allows for few daily doses
Clinical effects:
* Improves bradykinesia and rigidity
* (SO, Tremor can improve, but bradykinesia and rigidity really improve)
Long-term adverse effects
* “Wearing off” phenomenon
* “on-off” phenomenon ( sudden unpredictable changes in mobility)
* Dyskinensias (involuntary movements, associated with long-term Levodopa use)
What is the “75mg/day” rule for Carbidopa?
At least 75mg/day is required to effectively inhibit peripheral dopamine decarboxylase and allow levodopa to cross the BBB.
Dopamine Agonists
Available Agents
- Bromocriptine
- Pergolide
- Pramipexole (also used for restless leg)
- Ropinirole (also used for restless leg)
Clinical Pharmacology
- Directly stimulate dopamine receptors
1. * D2 receptor agonists
2. * Bromocriptine and pergolide are also ergot derivatives and also are D1 partial antagonists
- Used as initial therapy or adjunctive to Levodopa (to reduce off time or prolong on-time)
Anticholinergics (for PD)
Typical agents
* Trihexyphenidyl
* Benztropine
* others
Clinical Pharmacology
* Block muscarininc receptors in the striatum
* Reduces striatal activity
Modest effect on treating symptoms
* More beneficial for tremors
great for tremor, but less beneficial for bradykinesia.
–> More used for tremors he said
Amantadine (for PD)
Clinical Pharmacology
* Enhances dopamine release
* Blocks reuptake
* Stimualtes receptors
Clinical Effects
* Improves tremor, rigidity, and bradykinesia
* Adjunctive therapy in advanced disease
* Possible initial therapy for mild disease
Contrast “Simple Partial” vs. “Complex Partial” seizures.
Simple: No loss of consciousness; regional motor or non-motor symptoms.
Complex: Altered level of consciousness, often preceded by an aura.
Define the PD “wearing off” and “on-off” phenomena.
Wearing off: Loss of drug effect at the end of a dosing interval.
On-off: Sudden, unpredictable periods of poor mobility (off) and good mobility (on).
Primary indication for using COMT inhibitors (e.g., Entacapone, Tolcapone) in PD?
They are used as adjuncts to Levodopa/Carbidopa to increase the half-life and availability of levodopa.
Clinical Pharmacology
* Blocks the metabolism of dopamine and levodopa therefore can increase availability of levodopa
* Improves half-live of levodopa = lengthens time taken to break them down
Differentiate between a “simple partial” and “complex partial” seizure.
Simple: No loss of consciousness; symptoms are regional (motor or sensory).
Complex: Altered level of consciousness, often preceded by an aura.